GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alterola Biotech Inc (OTCPK:ABTI) » Definitions » Debt-to-Revenue

Alterola Biotech (Alterola Biotech) Debt-to-Revenue : N/A (As of Dec. 2023)


View and export this data going back to 2009. Start your Free Trial

What is Alterola Biotech Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Alterola Biotech's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.24 Mil. Alterola Biotech's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil. Alterola Biotech's annualized Revenue for the quarter that ended in Dec. 2023 was $0.00 Mil.


Alterola Biotech Debt-to-Revenue Historical Data

The historical data trend for Alterola Biotech's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alterola Biotech Debt-to-Revenue Chart

Alterola Biotech Annual Data
Trend Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Mar22 Mar23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only N/A N/A N/A N/A N/A

Alterola Biotech Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A N/A N/A N/A

Competitive Comparison of Alterola Biotech's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Alterola Biotech's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alterola Biotech's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Alterola Biotech's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Alterola Biotech's Debt-to-Revenue falls into.



Alterola Biotech Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Alterola Biotech's Debt-to-Revenue for the fiscal year that ended in Mar. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(1.26 + 0.154) / N/A
=N/A

Alterola Biotech's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2023) Revenue data.


Alterola Biotech Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Alterola Biotech's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Alterola Biotech (Alterola Biotech) Business Description

Traded in Other Exchanges
N/A
Address
47 Hamilton Square, Birkenhead, Merseyside, GBR, CH41 5AR
Alterola Biotech Inc is a development stage company. The company develops chewing gums to deliver nutraceutical/functional ingredients for applications such as appetite suppressant, cholesterol suppressant, vitamin delivery, antioxidant delivery, and motion sickness suppressant.
Executives
Bright Green Corp 10 percent owner 401 EAST LAS OLAS BLVD., SUITE 1400, FT. LAUDERDALE FL 33301